Inovio’s Covid-19 vaccine data remain a mystery
The first generation of Covid-19 vaccine candidates has made the trip from first injection to detailed Phase 1 data, giving the world’s virologists and immunologists, whether real or armchair, plenty to discuss.
That is, with one exception: Inovio Pharmaceuticals, which completed enrollment in April and declared victory via press release in June, is yet to publish its Phase 1 results. Yesterday, in concurrence with its quarterly earnings report, Inovio said its data were “currently undergoing peer review for publication at a top medical journal” and didn’t explain further.
Inovio stands out among its peers for providing particularly scant information in its initial press release. In June, the company said its vaccine led to “immunological response rates” in 34 of 36 patients in the trial, but did not disclose how many patients produced antibodies that neutralize the coronavirus, which would be key to determining whether the vaccine might protect against infection.
That is, with one exception: Inovio Pharmaceuticals, which completed enrollment in April and declared victory via press release in June, is yet to publish its Phase 1 results. Yesterday, in concurrence with its quarterly earnings report, Inovio said its data were “currently undergoing peer review for publication at a top medical journal” and didn’t explain further.
Inovio stands out among its peers for providing particularly scant information in its initial press release. In June, the company said its vaccine led to “immunological response rates” in 34 of 36 patients in the trial, but did not disclose how many patients produced antibodies that neutralize the coronavirus, which would be key to determining whether the vaccine might protect against infection.
.png)
No hay comentarios:
Publicar un comentario